文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a)水平升高影响家族性高胆固醇血症的诊断。

Elevated Lipoprotein(a) Level Influences Familial Hypercholesterolemia Diagnosis.

作者信息

Chubykina Uliana V, Ezhov Marat V, Afanasieva Olga I, Klesareva Elena A, Pokrovsky Sergei N

机构信息

A.L. Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.

Institute of Experimental Cardiology, National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.

出版信息

Diseases. 2022 Jan 18;10(1):6. doi: 10.3390/diseases10010006.


DOI:10.3390/diseases10010006
PMID:35225859
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8884002/
Abstract

Familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] level are the most common inherited disorders of lipid metabolism. This study evaluated the impact of high Lp(a) level on accuracy Dutch Lipid Clinic Network (DLCN) criteria of heterozygous FH diagnosis. A group of 206 individuals not receiving lipid-lowering medication with low-density lipoprotein cholesterol (LDL-C) >4.9 mmol/L was chosen from the Russian FH Registry. LDL-C corrected for Lp(a)-cholesterol was calculated as LDL-C − 0.3 × Lp(a). DLCN criteria were applied before and after adjusting LDL-C concentration. Of the 206 patients with potential FH, a total of 34 subjects (17%) were reclassified to less severe FH diagnosis, 13 subjects of them (6%) were reclassified to “unlike” FH. In accordance with Receiver Operating Characteristic curve, Lp(a) level ≥40 mg/dL was associated with FH re-diagnosing with sensitivity of 63% and specificity of 78% (area under curve = 0.7, 95% CI 0.7−0.8, p < 0.001). The reclassification was mainly observed in FH patients with Lp(a) level above 40 mg/dL, i.e., 33 (51%) with reclassified DLCN criteria points and 22 (34%) with reclassified diagnosis, compared with 21 (15%) and 15 (11%), respectively, in patients with Lp(a) level less than 40 mg/dL. Thus, LDL-C corrected for Lp(a)-cholesterol should be considered in all FH patients with Lp(a) level above 40 mg/dL for recalculating points in accordance with DLCN criteria.

摘要

家族性高胆固醇血症(FH)和脂蛋白(a)[Lp(a)]水平升高是最常见的遗传性脂质代谢紊乱。本研究评估了高Lp(a)水平对荷兰脂质诊所网络(DLCN)杂合子FH诊断标准准确性的影响。从俄罗斯FH登记处选取了一组206名未接受降脂药物治疗且低密度脂蛋白胆固醇(LDL-C)>4.9 mmol/L的个体。校正Lp(a)胆固醇后的LDL-C计算为LDL-C - 0.3×Lp(a)。在调整LDL-C浓度前后应用DLCN标准。在206例潜在FH患者中,共有34名受试者(17%)被重新分类为病情较轻的FH诊断,其中13名受试者(6%)被重新分类为“不像”FH。根据受试者工作特征曲线,Lp(a)水平≥40 mg/dL与FH重新诊断相关,敏感性为63%,特异性为78%(曲线下面积 = 0.7,95% CI 0.7 - 0.8,p < 0.001)。重新分类主要见于Lp(a)水平高于40 mg/dL的FH患者,即33例(51%)DLCN标准点数重新分类,22例(34%)诊断重新分类,而Lp(a)水平低于40 mg/dL的患者分别为21例(15%)和15例(11%)。因此,对于所有Lp(a)水平高于40 mg/dL的FH患者,应考虑校正Lp(a)胆固醇后的LDL-C,以便根据DLCN标准重新计算点数。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3970/8884002/94e349d91542/diseases-10-00006-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3970/8884002/d3b98059bc4f/diseases-10-00006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3970/8884002/518818467c0b/diseases-10-00006-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3970/8884002/b60abb5deff0/diseases-10-00006-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3970/8884002/94e349d91542/diseases-10-00006-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3970/8884002/d3b98059bc4f/diseases-10-00006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3970/8884002/518818467c0b/diseases-10-00006-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3970/8884002/b60abb5deff0/diseases-10-00006-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3970/8884002/94e349d91542/diseases-10-00006-g004.jpg

相似文献

[1]
Elevated Lipoprotein(a) Level Influences Familial Hypercholesterolemia Diagnosis.

Diseases. 2022-1-18

[2]
Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?

Clin Chem. 2019-7-15

[3]
The effect of adjusting LDL-cholesterol for Lp(a)-cholesterol on the diagnosis of familial hypercholesterolaemia.

J Clin Lipidol. 2023

[4]
Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation.

Clin Biochem. 2020-12

[5]
Low-density lipoprotein apheresis: an evidence-based analysis.

Ont Health Technol Assess Ser. 2007

[6]
Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia.

Atherosclerosis. 2023-1

[7]
A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia.

Clin Cardiol. 2019-8-22

[8]
Familial Hypercholesterolemia, Familial Combined Hyperlipidemia, and Elevated Lipoprotein(a) in Patients With Premature Coronary Artery Disease.

Can J Cardiol. 2021-11

[9]
Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia.

J Atheroscler Thromb. 2025-1-1

[10]
Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a).

Lipids Health Dis. 2022-11-2

引用本文的文献

[1]
Feature Paper Special Issue for Editorial Board Members (EBMs) of .

Diseases. 2022-3-22

本文引用的文献

[1]
Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation.

Clin Biochem. 2020-12

[2]
Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.

J Intern Med. 2020-1

[3]
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Eur Heart J. 2020-1-1

[4]
Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?

Clin Chem. 2019-7-15

[5]
Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.

Curr Pharm Des. 2018

[6]
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.

Atherosclerosis. 2018-10

[7]
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

J Am Coll Cardiol. 2018-1-16

[8]
Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis.

BMJ Open. 2017-9-1

[9]
Lipoprotein(a) apheresis.

Curr Opin Lipidol. 2016-8

[10]
High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.

Lancet Diabetes Endocrinol. 2016-5-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索